For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?.

Acta Neuropathol.. 2014-06;  127(6):803-10
Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, McLean CA, Villemagne VL, Parker MW, Barnham KJ, Miles LA. Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, Melbourne, VIC, 3010, Australia.
Products/Services Used Details Operation


Reducing amyloid-β peptide (Aβ) burden at the pre-symptomatic stages of Alzheimer's disease (AD) is currently the advocated clinical strategy for treating this disease. The most developed method for targeting Aβ is the use of monoclonal antibodies including bapineuzumab, solanezumab and crenezumab. We have synthesized these antibodies and used surface plasmon resonance (SPR) and mass spectrometry to characterize and compare the ability of these antibodies to target Aβ in transgenic mouse tissue as well as human AD tissue. SPR analysis showed that the antibodies were able to bind Aβ with high affinity. All of the antibodies were able to bind Aβ in mouse tissue. However, signifi... More


Alzheimer's disease; β-Amyloid; Bapineuzumab; Crenezumab; Solanezumab; Mass spectrometry